|
|
Article: Enzo Biochem Reports on Favorable Clinical Trial of EGS21 for Treatment of Non-Alcoholic Steatohepatitis.(Clinical report)
- Article from:
- Hepatitis Weekly
- Article date:
- November 16, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Enzo Biochem Inc. (NYSE:ENZ) announced that favorable results of the Company's clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo's orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome (see also Enzo Biochem Inc.).
Enzo scientists and collaborators presented data showing that "oral administration of EGS21 appears to be safe and biologically active in ...
Related newspaper, magazine, and journal articles:
|
|
Article: Enzo Biochem announces FDA marketing approval for ...
PR Newswire;
December 21, 1987 ;
700+ words
...ENZO BIOCHEM ANNOUNCES FDA MARKETING APPROVAL FOR ... NEW YORK, Dec. 21 /PRNewswire/ -- Enzo Biochem, Inc. (NASDAQ: ENZO), a New York ... virus. Elazar Rabbani, president of Enzo Biochem, stated, "This CMV kit, the second ...
|
|